Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence. - Wikidata - wikimedia - TriplyDB

Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence.

Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence.

http://www.wikidata.org/entity/Q33921802

about

Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer.Statistical research on the bioactivity of new marine natural products discovered during the 28 years from 1985 to 2012.

P2860

Q33801643-BB939883-ADDB-4300-9592-05DAE3A4ABAC Q35015321-18176DA2-F962-4859-9B0E-79897A6593C8

P2860

Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence.

http://www.wikidata.org/entity/Q33921802

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence.

@ast

Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence.

@en

type

label

Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence.

@ast

Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence.

@en

prefLabel

Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence.

@ast

Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence.

@en

P1433

Q33921802-CF7C2936-DE5C-4072-AC9F-63DFA23366F9

P1476

Q33921802-C2C0A31F-5F9C-42D0-BC5D-5D5FAD1EAE4E

P2093

Q33921802-0BBCB45E-96DF-4F29-80E9-2676C5FA7243

Q33921802-2201F181-52EE-41A1-88E4-88D3F3EABB1B

Q33921802-3C72149E-03C8-4278-AF5A-5A8FD60A725A

Q33921802-4615B2F1-4250-4E83-B41A-13D35C6E28EB

Q33921802-6654F773-3E31-4EE5-B205-88CD32813194

Q33921802-AD6F81EC-CCF0-4A4F-9738-7121E53FE1A3

Q33921802-BC07EB20-444B-43B7-801C-3F3B0288D09C

Q33921802-E45ADAC7-980E-4FE1-A9CD-271250C76C56

Q33921802-EAE7681D-25A5-4781-84F5-A0F40C692B0B

P2860

Q33921802-039A4B0D-A8D4-47B1-91EA-F0F9DB014790

Q33921802-03A0A131-A124-4187-9801-7A8800C31818

Q33921802-06FB6017-D570-4237-AFDC-1674B00D3AEE

Q33921802-08541903-167C-4F91-8A6F-3E3AF60E77BC

Q33921802-08A66BDD-4253-4656-BE57-2753DDA0942E

Q33921802-0ABAD4EC-4318-4BE1-8883-234D9F74C7BF

Q33921802-1089EF01-76FC-4BE3-8665-B1EC617D32DD

Q33921802-16A00873-3AFA-4371-AF5C-F070503F1160

Q33921802-1F17DF47-583A-48C4-876B-3E05E7783C09

Q33921802-26BEB869-D4EA-482D-8411-B9C0925C1420

P304

Q33921802-5FBAB37D-1593-49B4-88BB-1AF90E1C82E4

P31

Q33921802-9810A13A-DBC3-485E-8BA8-EF40FF2727E9

P356

Q33921802-94D34BB1-D42C-4FFD-A9DE-BC316889BE50

P407

Q33921802-96557B22-7150-45C2-9D44-2711900EDFC3

P478

Q33921802-7AF2EE89-4338-49ED-AED0-A338D972B22A

P50

Q33921802-6871EA3B-24E2-4614-8635-F45EADFB394F

Q33921802-E5668476-1856-4A72-832E-BB74CC9AF6D0

Q33921802-F2D846EC-C3D7-4EAB-A2DD-D24A842A55A7

P577

Q33921802-10AE85FF-6298-4463-9898-D2E6029B7381

P698

Q33921802-E9C2A826-F86A-4FAF-863D-FC5B8E78751E

P921

Q33921802-3D8A10D9-4180-4797-B7BD-F6502C41C557

Q33921802-CD2E8D50-0064-4AF6-B66E-47A6B4E50388

P932

Q33921802-A5B9AD2C-FD47-4D50-BB43-449B8EC2B066

P356

P1433

OncoTargets and Therapy

P1476

Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence

@en

P2093

Alessia Di Legge

http://www.w3.org/2001/XMLSchema#string

Carmine Conte

http://www.w3.org/2001/XMLSchema#string

Floriana Mascilini

http://www.w3.org/2001/XMLSchema#string

Giovanni Scambia

http://www.w3.org/2001/XMLSchema#string

Giulia Amadio

http://www.w3.org/2001/XMLSchema#string

Manuela Ludovisi

http://www.w3.org/2001/XMLSchema#string

Maria Grazia Di Stefano

http://www.w3.org/2001/XMLSchema#string

Valeria Masciullo

http://www.w3.org/2001/XMLSchema#string

Vanda Salutari

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2014

Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans

Cost-effectiveness of trabectedin plus pegylated liposomal doxorubicin for the treatment of women with relapsed platinum-sensitive ovarian cancer in the UK: analysis based on the final survival data of the OVA-301 trial.

Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.

Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.

Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.

Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.

Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.

Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study.

Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.

P304

1273-1284

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S51550

http://www.w3.org/2001/XMLSchema#string

P407

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Rosa De Vincenzo

P577

2014-07-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25050069

http://www.w3.org/2001/XMLSchema#string

P921

P932

4103925

http://www.w3.org/2001/XMLSchema#string